|
Characteristics
|
Case control cohorts
|
|---|
| |
Patients surviving
|
Patients surviving
|
|---|
| |
> 18 months (n = 40)
|
≤ 18 months (n = 40)
|
|---|
| |
(2000-2005)
|
(2000-2005)
|
|---|
|
Age (years)
| | |
|
< 50
|
12(30%)
|
9 (23%)
|
|
≥ 50
|
28(70%)
|
31(77%)
|
|
Gender
| | |
|
Male
|
24(60%)
|
24(60%)
|
|
Female
|
16(40%)
|
16(40%)
|
|
RPA class
| | |
|
III-IV
|
28(70%)*
|
10(25%)*
|
|
V-VI
|
12(30%)
|
30(75%)
|
|
Extent of surgery
| | |
|
Partial
|
3 (7.5%)
|
9 (22.5%)
|
|
Radical
|
37(92.5%)#
|
31(77.5%)#
|
|
Gammaknife
| | |
|
No
|
28(70%)
|
35(87.5%)
|
|
Yes
|
12(30%)
|
5 (12.5%)
|
|
RT + Temozolomide
| | |
|
No
|
32(80%)
|
39(97%)
|
|
yes
|
8 (2%)
|
1 (3%)
|
|
RT + adjuvant chemotherapy
| | |
|
No
|
17(42%)
|
21(52%)
|
|
Yes
|
23(58%)
|
19(48%)
|
|
Median follow-up time of those alive at study closure (months)
|
48 (n = 15)
|
0 (n = 0)
|
- A significant association was observed between RPA III-VI and number of patients with overall survival > 18 months *: p < .0001. No significant association was observed between radical surgery and longer patients survival #: p .06 (Chi-Square test)
